Lotilibcin

Cyclic Lipodepsipeptide (polymyxin Related Antibiotic)Rx: InvestigationalCompound: Investigational

Also known as: Lotilibcin, WAP-8294A, WAP-8294A2

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Lotilibcin (WAP-8294A2) is a cyclic lipodepsipeptide antibiotic derived from Lysobacter sp. with potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens, as well as some Gram-negative bacteria. It has been evaluated in early-phase clinical trials for the treatment of serious Gram-positive infections including bacteremia.

Mechanism of Action

Disrupts bacterial cell membrane integrity by binding to lipopolysaccharide (LPS) and phospholipids in the outer membrane of Gram-negative bacteria, leading to membrane permeabilization and bacterial cell death.

Routes of Administration

Intravenous

Goals & Uses

  • Treatment of serious Gram-positive infectionsAntibacterial / Infectious DiseaseModerate
  • Treatment of MRSA bacteremiaAntibacterial / Infectious DiseaseModerate
  • Treatment of vancomycin-resistant Enterococcus (VRE) infectionsAntibacterial / Infectious DiseaseLow
  • Alternative to vancomycin for resistant organismsAntibacterial / Infectious DiseaseLow

Contraindications

  • Severe pre-existing renal impairmentRenalModerate
  • Known hypersensitivity to lotilibcin or related lipodepsipeptidesAllergyHigh

Adverse Effects

  • NeurotoxicityNeurologicalRare
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
  • Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
  • NephrotoxicityRenalUncommon
  • Infusion-site reactionsLocal / AdministrationCommon

Drug Interactions

  • AminoglycosidesModerate
  • VancomycinModerate
  • NSAIDsLowMay increase renal risk in susceptible patients

Population Constraints

  • Pediatric patientsAgeRelative
  • Patients with renal impairmentOrgan ImpairmentRelative
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionInvestigationalNot EMA approved; no marketing authorization granted.
  • United StatesInvestigationalNot FDA approved; investigational use only.
  • United KingdomInvestigationalNot approved by MHRA; investigational status.

Investigational drug; has received limited regulatory designations. Phase I/II clinical trials have been conducted primarily in Asia. Not approved in any jurisdiction as of knowledge cutoff.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack